Rovius10 mg

Rovius is an HMG-CoA reductase inhibitor (statin) indicated for the following uses:

Established / FDA-approved uses

• Primary hyperlipidemia and mixed dyslipidemia: As an adjunct to diet, to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B, non-HDL-cholesterol, and triglycerides, and to increase HDL-cholesterol in adult and pediatric patients.
• Hypertriglyceridemia: As an adjunct to diet for treatment of adults with elevated triglyceride levels.
• Homozygous familial hypercholesterolemia (HoFH): To reduce LDL-cholesterol, total cholesterol, and apolipoprotein B, either alone or as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) when such treatments are unavailable or inadequate.
• Heterozygous familial hypercholesterolemia (HeFH) in pediatric patients: As an adjunct to diet to reduce LDL-cholesterol.

Guideline-supported / adjunct use

• Primary prevention of cardiovascular disease: In patients without clinically evident coronary heart disease but with an increased risk based on age and the presence of specific risk factors, Rovius is used to reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures.
• Slowing the progression of atherosclerosis: As part of a treatment strategy to lower total cholesterol and LDL-cholesterol in patients with hypercholesterolemia at risk of atherosclerosis.

Rovius is not indicated for the treatment of acute coronary events and does not substitute for diet, exercise, weight control, or other cardiovascular risk-factor management.

Each film-coated tablet contains Rosuvastatin Calcium equivalent to rosuvastatin as the active ingredient, commonly available in strengths of 5 mg, 10 mg, 20 mg, and 40 mg.

Tablets also contain standard pharmaceutical excipients such as microcrystalline cellulose, lactose monohydrate, calcium phosphate, crospovidone, magnesium stearate, and a film-coating system; exact excipients vary by manufacturer.

Rovius is a synthetic lipid-lowering agent belonging to the statin class. It is used for the management of dyslipidemia and for reducing the risk of cardiovascular events in appropriately selected patients.

Rovius works by inhibiting an enzyme in the liver that is essential for cholesterol synthesis, leading to increased uptake and catabolism of LDL-cholesterol. It is administered orally, once daily, with or without food, and is available as immediate-release film-coated tablets.

HMG-CoA Reductase Inhibitor (Statin) — Rovius belongs to this class of lipid-lowering agents.

Mechanism of Action

Rosuvastatin Calcium is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of cholesterol. Inhibition of this enzyme reduces hepatic cholesterol synthesis, increases the number of hepatic LDL receptors on the cell surface, and enhances uptake and catabolism of LDL from the blood, resulting in reductions in LDL-cholesterol, total cholesterol, apolipoprotein B, and triglycerides, with an increase in HDL-cholesterol.

Pharmacokinetics

• Absorption: Peak plasma concentrations are reached approximately 3-5 hours after oral dosing; absolute bioavailability is approximately 20%.
• Distribution: Approximately 88% bound to plasma proteins; extensively taken up by the liver, its primary site of action.
• Metabolism: Not extensively metabolized; approximately 10% undergoes metabolism, primarily via CYP2C9, to a minor active metabolite.
• Elimination: Eliminated mainly unchanged in the feces (via biliary excretion), with a small proportion excreted in urine; elimination half-life is approximately 19 hours.

• Take Rovius orally, once daily, at any time of day, with or without food.
• Swallow the tablet whole with water; do not crush or chew unless directed otherwise by a physician.
• If also taking an aluminum- or magnesium-hydroxide-containing antacid, take the antacid at least 2 hours after Rovius to avoid reduced absorption.
• Try to take the dose at the same time each day to maintain consistent blood levels.
• If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; do not double the dose.

Rovius has the following well-documented, clinically significant interactions:

• Cyclosporine: Significantly increases Rovius plasma exposure (several-fold). Concomitant use increases myopathy risk; limit Rovius dose to 5 mg once daily.
• Gemfibrozil and other fibrates: Increase Rovius exposure and substantially raise the risk of myopathy/rhabdomyolysis; avoid combination when possible or use the lowest effective dose with close monitoring.
• Protease inhibitors (e.g., lopinavir/ritonavir, atazanavir/ritonavir): Increase Rovius plasma levels; dose limitation is required.
• Warfarin and other vitamin K antagonists: Rovius may increase INR; monitor INR closely when starting or adjusting the dose of Rovius in patients on anticoagulants.
• Aluminum/magnesium hydroxide antacids: Reduce Rovius plasma concentration by roughly half if taken simultaneously; separate dosing by at least 2 hours.
• Niacin (lipid-modifying doses): May increase the risk of skeletal muscle effects when combined with Rovius.

Inform your physician of all prescription medicines, over-the-counter products, and supplements before starting Rovius.

Most patients tolerate Rovius well. Reported adverse effects include:

Common

• Headache
• Myalgia (muscle aches)
• Abdominal pain, nausea, constipation
• Asthenia (weakness)
• Dizziness

Less common / serious (see also Precautions and Warnings)

• Elevated liver transaminases
• Myopathy, and rarely rhabdomyolysis
• Immune-mediated necrotizing myopathy (very rare)
• Hypersensitivity reactions, including rash, pruritus, urticaria, and rarely angioedema
• New-onset hyperglycemia/diabetes (small increase in fasting glucose and HbA1c has been reported, a recognized class effect)
• Proteinuria and/or microscopic hematuria (usually transient, more common at the 40 mg dose)
• Thrombocytopenia (rare)

Seek prompt medical attention for unexplained muscle pain, tenderness or weakness accompanied by fever or dark urine, or signs of an allergic reaction.

Rovius is contraindicated in pregnancy. Statins, including Rovius, may cause fetal harm because cholesterol and other products of cholesterol biosynthesis are essential to fetal development; safety data in pregnant women are insufficient to rule out risk. If a patient becomes pregnant while taking Rovius, the medication should be discontinued immediately and the patient counselled about the potential risk to the fetus.

Rovius is also contraindicated during breastfeeding. It is not known whether Rovius is excreted in human milk, but because of the potential for serious adverse reactions in a nursing infant, women who require Rovius therapy should not breastfeed. A decision should be made, in consultation with a physician, whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.

Skeletal muscle effects (myopathy and rhabdomyolysis)

Rovius, like other statins, can cause myopathy (muscle pain, tenderness or weakness with creatine kinase elevation) and, rarely, rhabdomyolysis with acute kidney injury, which can be fatal. Risk is increased with higher doses, advanced age (≥65 years), renal impairment, hypothyroidism, and concomitant use of certain interacting drugs (see Interactions). Rare cases of immune-mediated necrotizing myopathy have also been reported. Discontinue promptly if myopathy is diagnosed or suspected, or if markedly elevated creatine kinase occurs.

Hepatic effects

Persistent elevations in serum transaminases can occur. Liver function tests should be performed before starting therapy and as clinically indicated thereafter. Rovius should be used with caution in patients who consume substantial amounts of alcohol and/or have a history of liver disease, and is contraindicated in active liver disease (see Contraindications).

Asian ancestry

Plasma concentrations of Rovius are higher in patients of Asian ancestry compared with other populations; a lower starting dose (5 mg once daily) is recommended for these patients.

Endocrine effects

Increases in HbA1c and fasting serum glucose have been reported with statin use, including Rovius; monitor blood glucose, particularly in patients at risk of diabetes.

Renal effects

Proteinuria and microscopic hematuria have been observed, usually transient, and more frequent at the 40 mg dose; consider dose reduction if unexplained persistent proteinuria develops during routine urinalysis.

Use Rovius only under medical supervision, with periodic monitoring of lipid levels and, when indicated, liver function and renal status.

There is no specific antidote for Rovius overdose. In the event of a suspected overdose, seek immediate medical attention or contact a poison control center. Treatment should be symptomatic and supportive, with monitoring of liver function and creatine kinase as clinically indicated. Hemodialysis is not expected to significantly enhance clearance of Rovius due to its high protein binding.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment

No dose adjustment is needed in mild to moderate renal impairment. In severe renal impairment (creatinine clearance <30 mL/min) not on hemodialysis, start Rovius at 5 mg once daily and do not exceed 10 mg once daily.

Hepatic impairment

Rovius is contraindicated in active liver disease (see Contraindications). Use with caution in patients with a history of liver disease; it has not been studied in severe hepatic impairment.

Elderly

No dose adjustment based on age alone is required, but plasma concentrations are higher and the risk of myopathy is increased in patients ≥65 years; use the lowest effective dose and monitor closely.

Asian ancestry

A lower starting dose (5 mg once daily) is recommended due to higher observed plasma exposure (see Precautions and Warnings).

Pediatric use

See Pediatric Uses for age-specific indications and dosing.

Rovius is generally used long-term as part of chronic management of dyslipidemia and cardiovascular risk reduction. Duration of therapy should be determined by a physician based on lipid response, tolerability, and ongoing cardiovascular risk assessment; treatment is often continued indefinitely alongside diet and lifestyle measures unless contraindications, intolerance, or a change in clinical status arises. Do not stop treatment without consulting a physician, even if cholesterol levels normalize, as levels may rise again after discontinuation.

Rosuvastatin Calcium belongs to the HMG-CoA reductase inhibitor (statin) class of lipid-lowering medicines.

Rosuvastatin Calcium competitively inhibits HMG-CoA reductase, the enzyme controlling the rate-limiting step in hepatic cholesterol biosynthesis. This reduces intracellular cholesterol, which upregulates hepatic LDL receptor expression, increasing clearance of LDL-cholesterol from the circulation and lowering total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides while modestly raising HDL-cholesterol.

X (FDA legacy pregnancy category) — contraindicated in pregnancy.

Use of Rovius in children is limited to specific, well-defined indications:

• Heterozygous familial hypercholesterolemia (HeFH): Approved for pediatric patients 8-17 years of age (girls who are at least 1 year post-menarche), as an adjunct to diet, at individualized doses generally between 5-20 mg once daily depending on age.
• Homozygous familial hypercholesterolemia (HoFH): Approved for pediatric patients 7-17 years of age at a dose of 20 mg once daily, up to a maximum of 40 mg once daily, as an adjunct to other lipid-lowering treatments.

Safety and efficacy of Rovius have not been established in children below these age ranges or outside these specific indications. Growth and sexual maturation should be monitored periodically in pediatric patients on long-term therapy, as with other statins.